Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC-Reference-Cited by-同舟云学术

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Published:2023-06 Issue:6 Volume:18 Page:731-743
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Alessi Joao V.,Elkrief Arielle,Ricciuti Biagio,Wang Xinan,Cortellini Alessio,Vaz Victor R.,Lamberti Giuseppe,Frias Rosa L.,Venkatraman Deepti,Fulgenzi Claudia A.M.,Pecci Federica,Recondo Gonzalo,Di Federico Alessandro,Barrichello Adriana,Park Hyesun,Nishino Mizuki,Hambelton Grace M.,Egger Jacklynn V.,Ladanyi Marc,Digumarthy Subba,Johnson Bruce E.,Christiani David C.,Lin Xihong,Gainor Justin F.,Lin Jessica J.,Pinato David J.,Schoenfeld Adam J.,Awad Mark M.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

3. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial;Sezer;Lancet,2021

4. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020

5. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N Engl J Med,2019

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy;Journal of Chemotherapy;2024-09

2. Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy;Lung Cancer;2024-09

3. Tumour mutational burden: clinical utility, challenges and emerging improvements;Nature Reviews Clinical Oncology;2024-08-27

4. Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC;Scientific Reports;2024-08-09

5. The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study;Cancer Management and Research;2024-08